Literature DB >> 10922300

Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors.

G D'Amico1.   

Abstract

Idiopathic immunoglobulin A nephropathy is characterized by an extreme variability in clinical course and sometimes by the unpredictability of the ultimate outcome. Among the numerous studies published in the last 15 years that have calculated the actuarial renal survival and tried to individuate the prognostic role of the clinical and histological features present at the onset of the disease or the time of biopsy, we chose to analyze critically the results of the most valid (30 studies). Actuarial renal survival at 10 years in adults was between 80% and 85% in most of the European and Asian studies, but it was less in studies from the United States and exceeded 90% in the few studies of children. Concordance existed in this selected literature that impairment of renal function, severe proteinuria, and arterial hypertension are the strongest and more reliable clinical predictors of an unfavorable outcome. However, analysis of the prognostic value of morphological lesions was more difficult because they have been characterized in some studies using an overall score or histological classes of progressively more severe involvement and, in others, using a semiquantitative grading of individual glomerular, tubular, interstitial, and vascular changes. In adult patients, a high score of glomerular and tubulointerstitial lesions, corresponding to classes IV and V of the Lee or Haas classifications, predicted a more rapid progression. When single lesions were analyzed separately, glomerulosclerosis and interstitial fibrosis appeared to be the strongest, most reliable predictors of unfavorable prognosis. More controversial was the role of crescents and capsular adhesions. None of the immunohistological features was found to be a risk factor for progression in the more accurate statistical analyses. The same histological features predicted outcome in children, although the severity of lesions at the time of biopsy was usually less than that in adults. However, in the single patient, even the evaluation of these prognostic markers sometimes fails to correctly predict outcome, probably because of the heterogeneity of the disease and the discontinuous activity of some injuring mechanisms during its course.

Entities:  

Mesh:

Year:  2000        PMID: 10922300     DOI: 10.1053/ajkd.2000.8966

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  138 in total

1.  T cell cytokines determine the severity of experimental IgA nephropathy by regulating IgA glycosylation.

Authors:  S R Chintalacharuvu; N U Nagy; N Sigmund; J G Nedrud; M E Amm; S N Emancipator
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

Review 2.  Progress in molecular and genetic studies of IgA nephropathy.

Authors:  J Novak; B A Julian; M Tomana; J Mesteck
Journal:  J Clin Immunol       Date:  2001-09       Impact factor: 8.317

3.  Gene polymorphisms contributing to hypertension in immunoglobulin A nephropathy.

Authors:  Maki Shinzawa; Ryohei Yamamoto; Yasuyuki Nagasawa; Tatsuya Shoji; Yoshitsugu Obi; Tomoko Namba; Harumi Kitamura; Tetsuya Kaneko; Noriyuki Okada; Hirotsugu Iwatani; Atsushi Yamauchi; Yoshiharu Tsubakihara; Enyu Imai; Yoshitaka Isaka; Hiromi Rakugi
Journal:  Clin Exp Nephrol       Date:  2011-11-11       Impact factor: 2.801

4.  High-dose intravenous immunoglobulin pulse therapy in patients with progressive immunoglobulin A nephropathy: a long-term follow-up.

Authors:  F M Rasche; F Keller; P M Lepper; C Aymanns; W Karges; L-C Sailer; L von Müller; D Czock
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

Review 5.  Corticosteroid therapy in IgA nephropathy.

Authors:  Jicheng Lv; Damin Xu; Vlado Perkovic; Xinxin Ma; David W Johnson; Mark Woodward; Adeera Levin; Hong Zhang; Haiyan Wang
Journal:  J Am Soc Nephrol       Date:  2012-04-26       Impact factor: 10.121

6.  Long-term results of a randomized controlled trial in childhood IgA nephropathy.

Authors:  Koichi Kamei; Koichi Nakanishi; Shuichi Ito; Mari Saito; Mayumi Sako; Kenji Ishikura; Hiroshi Hataya; Masataka Honda; Kazumoto Iijima; Norishige Yoshikawa
Journal:  Clin J Am Soc Nephrol       Date:  2011-04-14       Impact factor: 8.237

7.  Intermedin ameliorates IgA nephropathy by inhibition of oxidative stress and inflammation.

Authors:  Yanhong Wang; Jihua Tian; Haixiu Guo; Yang Mi; Ruijing Zhang; Rongshan Li
Journal:  Clin Exp Med       Date:  2015-04-28       Impact factor: 3.984

8.  Risk factors for persistent proteinuria after a 2-year combination therapy for severe childhood IgA nephropathy.

Authors:  Koichi Kamei; Koichi Nakanishi; Shuichi Ito; Kenji Ishikura; Hiroshi Hataya; Masataka Honda; Kandai Nozu; Kazumoto Iijima; Yuko Shima; Norishige Yoshikawa
Journal:  Pediatr Nephrol       Date:  2014-12-10       Impact factor: 3.714

9.  Expression of alpha5beta1 and alpha6beta1 integrins in IgA nephropathy (IgAN) with mild and severe proteinuria. An immunohistochemical study.

Authors:  Małgorzata Wagrowska-Danilewicz; Marian Danilewicz
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

10.  Histopathologic features aid in predicting risk for progression of IgA nephropathy.

Authors:  Michael Walsh; Aylin Sar; Diane Lee; Serdar Yilmaz; Hallgrimur Benediktsson; Braden Manns; Brenda Hemmelgarn
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-14       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.